These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809 [TBL] [Abstract][Full Text] [Related]
4. Preventing and Managing Toxicities of High-Dose Methotrexate. Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039 [TBL] [Abstract][Full Text] [Related]
5. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103 [TBL] [Abstract][Full Text] [Related]
6. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022 [TBL] [Abstract][Full Text] [Related]
7. Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels. Wyatt KD; Cooper J; Scott K; Broomall E; Altaf S; Hogan MC; Rodriguez V; Khan S J Pediatr Hematol Oncol; 2018 Mar; 40(2):152-155. PubMed ID: 29240024 [TBL] [Abstract][Full Text] [Related]
8. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. Tuffaha HW; Al Omar S J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686 [TBL] [Abstract][Full Text] [Related]
9. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature. Boelens AD; Mathôt RAA; Vlaar APJ; Bouman CSC Neth J Med; 2018 Jan; 76(1):36-39. PubMed ID: 29380731 [TBL] [Abstract][Full Text] [Related]
10. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data. Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862 [TBL] [Abstract][Full Text] [Related]
11. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. Truong HL; Barreto JN; Mara KC; Hampel PJ; Micallef IN; Nowakowski GS; Thanarajasingam G; Thompson CA; Wang Y; Witzig TE; Herrmann SM; Leung N JCO Oncol Pract; 2024 Jun; 20(6):797-807. PubMed ID: 38408299 [TBL] [Abstract][Full Text] [Related]
12. A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults? Domingo-González A; Osorio S; Landete E; Monsalvo S; Díez-Martín JL J Oncol Pharm Pract; 2021 Apr; 27(3):734-738. PubMed ID: 32731844 [TBL] [Abstract][Full Text] [Related]
13. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849 [TBL] [Abstract][Full Text] [Related]
14. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903 [TBL] [Abstract][Full Text] [Related]
15. Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase. Schultz TE; Lynch AC J Oncol Pharm Pract; 2019 Jun; 25(4):993-997. PubMed ID: 29651915 [TBL] [Abstract][Full Text] [Related]
16. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. Fermiano M; Bergsbaken J; Kolesar JM Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487 [TBL] [Abstract][Full Text] [Related]
17. Glucarpidase for the treatment of life-threatening methotrexate overdose. Tuffaha HW; Al Omar S Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306 [TBL] [Abstract][Full Text] [Related]
18. Glucarpidase following high-dose methotrexate: update on development. Patterson DM; Lee SM Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307 [TBL] [Abstract][Full Text] [Related]
19. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia. Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809 [TBL] [Abstract][Full Text] [Related]
20. A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Bielack SS; Soussain C; Fox CP; Houillier C; Murciano T; Osborne W; Zinzani PL; Rizzari C; Schwartz S J Cancer Res Clin Oncol; 2024 Oct; 150(10):441. PubMed ID: 39356310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]